University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
NCT Number: NCT06300996
Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with Type 2, 3, or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 2, 3, or 4 SMA aged 16 or older that show quantifiable motor deficits of the upper body. The investigators will then implant the subjects with percutaneous, linear spinal leads near the cervical spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.
This study is active but is not currently recruiting participants.
Notify Me16 year–65 year
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15213, United States
The investigators plan to 1. verify that spinal cord stimulation increases elbow muscle strength in subjects with SMA, 2. verify that spinal cord stimulation improves motor control in subjects with SMA, 3. verify that spinal cord stimulation induces measurable changes in spinal circuits and motoneuron recruitment properties in the 29 day course of implantation.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
SMA Participant Inclusion Criteria:
a. Can't stand independently.
Healthy Control Participant Inclusion Criteria:
SMA Participant Exclusion Criteria:
Healthy Control Participant Exclusion Criteria:
Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.
Time frame: 29 days
Isometric torque: measure the isometric torque produced by the subject at the elbow during flexion. The investigators will use the measurement of isometric torque to determine the changes in muscle strength for each participant with SCS on and with SCS off. This comparison will also include testing the non-affected arm to give the investigators a baseline for normal movement of the joint being tested. Success Criteria: ≥30% increased torque production over the SCS-off/non-affected baseline as measured during single-joint isometric torque.
Time frame: 29 days
Success Criteria: no serious adverse events related to the stimulation or intolerable. adverse events reported
Time frame: 29 days
Muscle activation: measure surface electromyogram (EMGs) produced by the subjects during isometric movements of the elbow in the HUMAC Norm and compare to SCS-on with SCS-off and non-affected SCS side performances. Meaningful Change: >20% EMG root-mean-square (RMS) compared to SCS-on.
Time frame: 29 days
Range of Motion (ROM): Meaningful Change: Increase of >20% of the elbow joint (if available) during SCS-on against SCS-off and SCS-non affected arm as measured by the HUMAC Norm during single-joint isotonic trials.
Time frame: 29 days
The Revised Upper Limb Module (RULM) for SMA is a further refined version of the Hammersmith Functional Motor Scale Extended and includes specific items focused on upper-limb motor control such as raising the arms above the head that are particularly relevant for the Type 2 population of the study, or those with further progressed Type 3 and Type 4. The scale is a performance evaluation with a total score ranging from 0, if none of the activities is achieved, to 37, if all the activities are achieved fully, so a higher score means a better outcome. For our study, we require participants to score at least a 4 to be eligible. Meaningful Change: ≥2 point improvement. Compare outcomes between SCS-on and SCS-off as well as the non-affected arm.
Time frame: 29 days
Fatigue will be assessed during motor function tests. Patients will be asked to provide a score from 1-10, where a greater number indicates a greater amount of fatigue for each stimulation configuration.
Time frame: 29 days
Patients will be asked to provide a score from 1-10, where a greater number indicates a greater amount of discomfort for each stimulation configuration. Spinal cord stimulation produces tingling sensations and other type of sensory phenomena. It is important to document that stimulation intensities required to improve motor function remain within a range of non-painful sensations.
Time frame: 29 days
The investigators will perform high-definition weighted imaging to quantify fractional anisotropy as a measurement of axon density in the brain and spinal cord pre and post study.
Time frame: 29 days
The investigators will collect subjects and therapist feedback on how the technology is performing and what they would want to modify using The Clinical Global Impression Scale, a scale of 1-7 where a lower number indicates better performance and a higher number indicates more greatly impacted by their disease.
Time frame: 29 days
The investigators will perform high-definition diffusion weighted imaging to quantify fractional anisotropy as a measurement of axon integrity in the brain and spinal cord pre and post study.
Time frame: 29 days
The investigators will perform resting state and motor-task functional MRI of the brain and spinal cord to quantify neural network activation at rest and during the execution of simple motor task such as leg muscle contraction.
Time frame: 29 days
The investigators will measure muscle evoked potential consequent to Transcranial Magnetic Stimulation of the cortico-spinal tract to assess the integrity of the cortico-spinal tract.
Time frame: 29 days
The investigators will measure H-reflexes of the arm muscles to quantify excitability of spinal motoneurons to stimulation of primary sensory afferents pre and post-study. Expected Result: Our main scientific hypothesis is that SCS will restore monosynaptic responses of weak spinal motoneurons, thus increasing H-reflex responses pre and post study.
Time frame: 29 days
The investigators will use high-density EMGs on leg muscles to calculate firing rates of single spinal motoneuron discharge during isometric maximal voluntary contractions.
Time frame: 29 days
The investigators will use high-density EMGs on arm muscles to calculate the number of firing rates of single spinal motoneuron discharge during isometric maximal voluntary contractions.
Marco Capogrosso
Other
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb Protocol
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05626855
Anti-myostatin, Atrophy
Phoenix, Arizona, United States
View Trial DetailsNCT03709784
Central Nervous System Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Phoenix, Arizona, United States
View Trial DetailsNCT07047144
Anti-myostatin, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05156320
Anti-myostatin, Atrophy
Birmingham, Alabama, United States
View Trial Details